Long-acting injectable antipsychotics (LAIs) compared
Every FDA-approved long-acting injectable antipsychotic compared: dose interval, initiation loading, oral coverage, price, and where each fits. Aripiprazole, paliperidone, risperidone, olanzapine, haloperidol, fluphenazine LAIs plus 3-month and 6-month options.
Second-generation LAIs (most commonly used)
Aripiprazole once monthly (Abilify Maintena): 400 mg IM every 4 weeks, standard. Initiation requires oral aripiprazole overlap for 14 days. Advantage: lowest metabolic risk among LAIs, partial-agonist mechanism, generally well tolerated. Disadvantage: significant activation/akathisia risk at initiation.
Aripiprazole lauroxil (Aristada, Aristada Initio): 441 mg, 662 mg, 882 mg every 4 weeks, or 882 mg every 6 weeks, or 1064 mg every 2 months. Initiation with Aristada Initio 675 mg IM plus one 30 mg oral aripiprazole dose, then Aristada by day 8 or 14 depending on protocol. Advantage: multiple dosing intervals, longer options available. Disadvantage: complex initiation options.
Paliperidone palmitate once monthly (Invega Sustenna): 234 mg IM day 1, 156 mg IM day 8, then 39 to 234 mg IM monthly. Advantage: no oral overlap required after loading doses. Disadvantage: highest first-week loading dose is deltoid, then monthly gluteal or deltoid.
Paliperidone palmitate every 3 months (Invega Trinza): after 4 monthly doses of Invega Sustenna, switch to Invega Trinza 273 to 819 mg IM every 3 months. Advantage: quarterly dosing dramatically simplifies adherence.
Paliperidone palmitate every 6 months (Invega Hafyera): FDA-approved 2021. 1092 or 1560 mg IM every 6 months, after prior stabilization on Invega Sustenna or Invega Trinza. Advantage: only 2 injections per year. Currently the longest-interval LAI available.
Risperidone microspheres (Risperdal Consta): 25 to 50 mg IM every 2 weeks. Oral risperidone continued for 3 weeks after first injection due to delayed release onset. Disadvantage: biweekly dosing is more frequent than newer options.
Risperidone extended-release (Perseris): 90 or 120 mg SC monthly. Advantage: subcutaneous injection.
Risperidone (Uzedy): FDA-approved 2023. 50 to 250 mg SC monthly or every 2 months. Newer subcutaneous option.
Risperidone (Rykindo): FDA-approved 2023. IM biweekly.
Olanzapine pamoate (Zyprexa Relprevv): 150 to 300 mg IM every 2 or 4 weeks. Requires 3-hour post-injection monitoring at healthcare facility due to post-injection delirium/sedation syndrome (PDSS) risk, rare but real. Restricted use.
First-generation LAIs (still used, particularly outside US)
Haloperidol decanoate: 25 to 100 mg IM every 4 weeks. Older but effective. Higher EPS/TD risk than second-generation LAIs.
Fluphenazine decanoate: 12.5 to 25 mg IM every 2 to 4 weeks. Similar to haloperidol.
Choosing between LAIs
Prior oral tolerability: Only start a LAI with a drug the patient has previously tolerated orally. Never switch a patient to a LAI of a drug they've never tried.
Metabolic profile priority: Aripiprazole LAIs and cariprazine LAIs (in development) have the lowest metabolic risk.
Adherence extremes: For maximum adherence support (patients with severe adherence barriers, criminal justice involvement, or homelessness), longer intervals help. Invega Trinza (3 months) and Invega Hafyera (6 months) are the longest available.
Initiation logistics: Some LAIs require oral overlap; some don't. Some require multiple loading injections. Match to what the patient can commit to.
Site of injection: All LAIs are intramuscular or subcutaneous. Deltoid vs gluteal availability matters for some.
Cost: LAIs are expensive. Payer coverage varies. Some are only covered for patients with documented adherence failure on oral.
Common questions
Why use a LAI instead of oral antipsychotic? Adherence. Patients with schizophrenia and bipolar disorder have real non-adherence rates of 40 to 60 percent on oral drugs. LAIs eliminate the daily decision. Long-term outcomes on LAIs are often better than oral in real-world data because adherence is much higher.
Are LAIs better than oral antipsychotics? For adherence, yes. For clinical efficacy at similar plasma levels, roughly equivalent. Real-world outcomes favor LAIs because adherence is dramatically higher.
Which LAI has the longest interval? Invega Hafyera (paliperidone palmitate every 6 months). Only 2 injections per year after stabilization on the every-1-month formulation.
Which LAI has the lowest metabolic risk? Aripiprazole LAIs (Abilify Maintena, Aristada, Aristada Initio). Partial-agonist mechanism produces less weight gain and metabolic dysregulation than paliperidone or risperidone.
Does olanzapine LAI cause a special reaction? Yes. Zyprexa Relprevv can cause post-injection delirium/sedation syndrome (PDSS) in rare cases (0.07 percent of injections), where the drug enters the bloodstream faster than intended. Requires 3-hour post-injection monitoring at a healthcare facility. This restriction has substantially limited use.
Can LAIs be used in bipolar disorder? Yes, for maintenance treatment of bipolar I disorder. Abilify Maintena, Aristada, Invega Sustenna, and Risperdal Consta all have bipolar maintenance indications. Adherence in bipolar is often a bigger issue than in schizophrenia.
What happens if a dose is missed? Depends on the drug and how much was missed. Each LAI has specific rules for missed dose management, generally involving assessment of the time since last dose and possible oral coverage. See the LAI class page for drug-specific missed-dose protocols.
Are LAIs expensive? Yes. List prices run several hundred to several thousand dollars per injection. Insurance coverage varies. Copay assistance programs exist for most branded LAIs.
Sources
- Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180.
- Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1-24.
- Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189-1205.
- FDA prescribing information for each LAI via DailyMed.
THE KNOWLEDGE PATH
Walk this topic outward.
- GUIDE Long-acting injectable antipsychotics (LAIs) compared (current)
- CLASS SSRIs
- MEDICATION Sertraline (Zoloft)
- CONDITION Major Depressive Disorder (on Shrinkopedia)
- CARE Depression care at shrinkMD
The Knowledge Path is a curated walk. Every step is one decision away from the next.
Managing a medication needs a prescriber
Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.